James Cullen

Does Aspreva Pharmaceuticals' Valuation Even Matter?

Excellent writing, and I love the mining stock analogy. Having also listened to the conference call, you can tell the slow pace of the BD is maddening to everyone following the stock, especially the analyst at Pacific Growth.
As much as Aspreva management is under fire to deliver soon, I think they have at least a year (until mid-2008) until serious worries start to kick in... not that I would encourage them to wait that long, but they generate a ton of cash flow and can ride CellCept a while longer. Right now though, the price puts it in definite value territory, and an eventual partnership will give it a growth kick and should take it upwards of $30.